Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Akira Kitamura, GM, AI Drug Development Division of NEC Corporation and CEO of NEC Bio, added, “This agreement is an important milestone in our partnership with Transgene and reflects NEC’s long-term commitment to the development of TG4050